By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Biogen Idec, Inc. (Massachusetts) 

225 Binney Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 781-464-2000 Fax: n/a


Biogen Idec (NASDAQ: BIIB) is a biotechnology leader that discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. With its rich scientific heritage and passionate commitment to pioneering new advances, Biogen Idec recognizes that cutting-edge science and medicines can address unmet patient needs to change the course of devastating diseases.

Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates nearly $5 billion in annual revenues. Biogen Idec has a strong late stage pipeline with the potential to launch new products for multiple sclerosis, amyotrophic lateral sclerosis (ALS) and hemophilia by 2015.

With about 4,800 employees worldwide, Biogen Idec is a truly global organization. In addition to our headquarters in Weston, Mass., and our research operations in Cambridge, Mass., we have a world-class manufacturing facility in North Carolina and offices in Canada, Australia, Japan and throughout Europe. We also have a direct commercial presence in more than 29 markets and a network of distribution partners in more than 70 additional markets, including new markets such as Central/Eastern Europe, Brazil, China and India.

For product labeling, press releases and additional information about the company, please visit




CEO: George A. Scangos, PhD

CMO: Alfred W. Sandrock, Jr., M.D., PhD

CFO: Paul J. Clancy


Please click here for Biogen job opportunities..


Please click here for clinical trial information.


Please click here for product information..


Key Statistics

Ownership: Public

Web Site: Biogen
Employees: 1700
Symbol: BIIB



NeoGenesis Pharmaceuticals, Inc.  Small molecule High Throughput Screening for multiple programs (6/01)

GPC Biotech, Inc.  HIV TAT-derived transport polytptides and methods of their use (5/01) - this was an outlicense from a research

ICOS Corporation  LFA-1 small molecule for psoriasis (7/01)

Elan  (crohn's & MS)

Dyax  Antibody phage display



Dow AgroSciences LLC 


Company News
Biogen (BIIB)'s Ex-CEO George Scangos Left a Very Wealthy Man 4/27/2017 6:26:55 AM
Biogen (BIIB) Earnings: New Drug Sparks Life 4/27/2017 6:10:26 AM
Some Predict Biogen (BIIB)’s Alzheimer’s Drug Will Fail 4/26/2017 6:03:49 AM
Biogen (BIIB) Reports First Quarter 2017 Revenues Of $2.8 Billion 4/25/2017 6:34:41 AM
Biogen (BIIB)’s SPINRAZA (Nusinersen) Receives Positive CHMP Opinion For The Treatment Of Spinal Muscular Atrophy 4/24/2017 6:35:35 AM
Biogen (BIIB) Release: TECFIDERA And TYSABRI Data Demonstrate Improved Outcomes With Early MS Treatment 4/24/2017 6:29:08 AM
Biogen (BIIB)'s Newly-Approved Spinraza Successful in Older Children With Spinal Muscular Atrophy 4/24/2017 5:59:55 AM
Fasten Your Seatbelt: Biogen (BIIB) Preps for a Deal-Making Bonanza 4/24/2017 5:55:32 AM
Biogen (BIIB) Highlights Advances From Its Neurology Research Programs And Portfolio Of Innovative Medicines At AAN Congress 4/18/2017 6:22:29 AM
How Biogen (BIIB) Lost Its Chance to Be the Hunter and Became the Hunted in Just a Few Months 4/17/2017 5:52:15 AM